Composition and method for treatment of autoimmune disease

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 39/395 (2006.01) A61K 38/17 (2006.01) C07K 14/705 (2006.01)

Patent

CA 2691784

The present invention provides compositions and methods for the treatment of autoimmune diseases, in particular rheumatoid arthritis. Compounds which function as antagonists of Toll-like Receptor 2 are shown to suppress the immune response which result in the onset and progression of autoimmune disease. In particular monoclonal antibodies which have a binding specificity to Toll-like receptor 2 are disclosed for use in methods for the treatment and/or prophylaxis of autoimmune disease.

La présente invention concerne des compositions et procédés de traitement de maladies auto-immunes, notamment la polyarthrite rhumatoïde. L'invention concerne des composés qui agissent en tant qu'antagonistes du récepteur Toll-like 2 pour supprimer la réponse immunitaire qui est induite par l'apparition et la progression de maladie immunitaire. L'invention concerne en particulier des anticorps monoclonaux qui présentent une liaison spécifique au récepteur Toll-like 2 destinés à être utilisés pour le traitement et/ou la prévention de maladie immunitaire.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Composition and method for treatment of autoimmune disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Composition and method for treatment of autoimmune disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for treatment of autoimmune disease will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1817967

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.